



an Open Access Journal by MDPI

Impact Factor 1.0

CiteScore 2.0

Hemato



[mdpi.com/
journal/
hemato](https://mdpi.com/journal/hemato)



Message from the Editor-in-Chief

Hematologists, hematopathologists, cellular biologists, immunologists, and molecular biologists are invited to contribute to *Hemato*, an international open access journal on hematology. Clinical data regarding diagnosis and management are primarily addressed to clinical specialists, while advances in pathogenesis, molecular epidemiology, genetics, immunogenetics, and immunotherapy about neoplastic and non-neoplastic blood diseases are primarily addressed to biologists, epidemiologists, pharmacologists, and immunologists.

Editor-in-Chief

Prof. Dr. Antonino Carbone

Section Editors-in-Chief

Dr. Alberto Signore

Dr. Anna Sureda

Dr. Grigoris T. Gerotziakas

Dr. Laurent Garderet

Aims

Hemato (ISSN 2673-6357) is an open access journal of scientific research on hematology that publishes regular research papers, reviews, communications, and case reports covering all aspects of hematology, from pathogenesis to diagnosis and personalized management. Our aim is to improve the study of clinical and basic research of blood-related diseases.

Scope

- Leukemias
- Lymphomas
- Amyloidosis
- Coagulation
- Plasma cell disorders
- Neoplastic and non-neoplastic blood disorders
- Immunotherapy
- Targeted therapy
- Cell transplantation
- SPECT, PET, CT, MRI and other diagnostic tests in hematological disorders

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

2024 Impact Factor: 1.0

(*Journal Citation Reports* - Clarivate, 2025)

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Coverage by Leading Indexing Services

ESCI (Web of Science), Scopus, EBSCO, and other databases

Rapid Publication

A first decision is provided to authors approximately 33.8 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025)

MDPI is a member of

CASPA



STM¹



SPARC*
Europe



DOAJ



ORCID

Affiliated Societies:

Spanish Society of Hematology and Hemotherapy (SEHH)
Nuclear Medicine Discovery (Nu.Me.D.)



Editorial Office

hemato@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

July 2025

